Form 8-K - Current report:
SEC Accession No. 0001213900-25-018867
Filing Date
2025-02-28
Accepted
2025-02-28 17:29:52
Documents
14
Period of Report
2025-02-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0232572-8k_onconetix.htm   iXBRL 8-K 37764
2 ONCONETIX, INC. CONSULTING AGREEMENT ea023257201ex99-1_onconetix.htm EX-99.1 35012
  Complete submission text file 0001213900-25-018867.txt   263703

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE onco-20250224.xsd EX-101.SCH 3042
4 XBRL LABEL FILE onco-20250224_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE onco-20250224_pre.xml EX-101.PRE 22377
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0232572-8k_onconetix_htm.xml XML 3795
Mailing Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202
Business Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202 513-620-4101
Onconetix, Inc. (Filer) CIK: 0001782107 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41294 | Film No.: 25692431
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)